NFKB1 and Miyoshi myopathy: For example, Aurora kinase family could be a potential target of MM treatment for the interaction with the key regulators of canonical and non‐canonical NF‐κB pathways,19 and the latter is a well acknowledged key mediator of MM carcinogenesis and drug resistance.20